BIP Capital Partners

Skip to content
  • HOME
  • About us
    • OUR TEAM
    • OUR HISTORY
    • ESG
    • BIP IV
  • investment approach
    • INVESTMENT APPROACH
    • INVESTMENT CHARACTERISTICS
  • portfolio
    • SELECTED INVESTMENTS
    • SELECTED EXITS
  • News
  • CONTACT

Enzymotec reports 3rd quarter 2014 unaudited financial results

Post navigation

Previous PostBIP invests in lifebrain AG, an Austrian-based medical diagnostic laboratory groupNext PostMoleskine announces first nine months 2014 results
© BIP Group Luxembourg 2025
Disclaimer